Elevation Oncology
ELEV
ELEV was delisted on the 22nd of July, 2025.
32 hedge funds and large institutions have $13.9M invested in Elevation Oncology in 2023 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 7 increasing their positions, 7 reducing their positions, and 10 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 7
5.24% less ownership
Funds ownership: 66.18% → 60.94% (-5.2%)
22% less funds holding
Funds holding: 41 → 32 (-9)
25% less capital invested
Capital invested by funds: $18.6M → $13.9M (-$4.7M)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
90% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$234K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$53.7K |
| 3 |
BlackRock
New York
|
+$22.9K |
| 4 |
Two Sigma Advisers
New York
|
+$13.7K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$2.07K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ECM
ExodusPoint Capital Management
New York
|
-$662K |
| 2 |
AC
Armistice Capital
New York
|
-$497K |
| 3 |
TCM
Tang Capital Management
San Diego,
California
|
-$176K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$132K |
| 5 |
Walleye Capital
New York
|
-$98.7K |
ELEV Hedge Fund Activity: Q4 2023 in Review
32 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in Elevation Oncology (ELEV) for Q4 2023, worth a combined $13.9M — down 25% from $18.6M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of ELEV and 1 opened new positions — a net loss of 9 holders — while 7 trimmed existing stakes and 7 added.
The largest buyer was Renaissance Technologies, opening a new position worth an estimated $234K. The largest seller was ExodusPoint Capital Management, exiting entirely with an estimated $662K sold.
- 32 institutional investors held Elevation Oncology (ELEV) as of Q4 2023, down from 41 in Q3 2023.
- Funds reported $13.9M of Elevation Oncology stock for Q4 2023, down 25% quarter-over-quarter.
- 1 fund opened new Elevation Oncology positions in Q4 2023 and 10 closed out, a net change of -9 holders.
- The largest Elevation Oncology buyer in Q4 2023 was Renaissance Technologies, an estimated $234K added.
- The largest Elevation Oncology seller in Q4 2023 was ExodusPoint Capital Management, an estimated $662K sold.
Based on aggregated 13F filings for Q4 2023.